Gliosarcoma as a rare variant of glioblastoma: 6-Case clinical trial and literature review

Gliosarcoma is a rare and highly malignant central nervous system tumor that accounts for 1% to 8% of glioblastomas; it usually occurs in middle-aged and older adults between 40 and 60 years of age and is rare in children. Here in, we present a retrospective study of 6 cases of gliosarcomas diagnosed at the Mohamed V Military Instruction Hospital (HMIMV). A review of clinical, radiological, therapeutic and evolutionary data was carried out. Treatment consisted of a complete macroscopic resection for 5 patients, completed with an adjuvant radiotherapy with temozolomide, the median survival time of our cases was 9,4 months. As a conclusion, there is a lack of a definitive treatment that significantly improves prognosis for gliosacroma’s tumor, so more case reports of GS should be conducted, which would allow a clearer diagnosis and improved treatment methods and prognoses.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-08-30
DOI
https://doi.org/10.5281/zenodo.14848708
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gliosarcoma as a rare variant of glioblastoma: 6-Case clinical trial and literature review

Zenodo (CERN European Organization for Nuclear Research)
Glioma Diagnosis and Treatment
article

Gliosarcoma as a rare variant of glioblastoma: 6-Case clinical trial and literature review

article en

Abstract

Gliosarcoma is a rare and highly malignant central nervous system tumor that accounts for 1% to 8% of glioblastomas; it usually occurs in middle-aged and older adults between 40 and 60 years of age and is rare in children. Here in, we present a retrospective study of 6 cases of gliosarcomas diagnosed at the Mohamed V Military Instruction Hospital (HMIMV). A review of clinical, radiological, therapeutic and evolutionary data was carried out. Treatment consisted of a complete macroscopic resection for 5 patients, completed with an adjuvant radiotherapy with temozolomide, the median survival time of our cases was 9,4 months. As a conclusion, there is a lack of a definitive treatment that significantly improves prognosis for gliosacroma’s tumor, so more case reports of GS should be conducted, which would allow a clearer diagnosis and improved treatment methods and prognoses.

Zenodo (CERN European Organization for Nuclear Research)
Mohammed V University (MA)
Good health and well-being
Openalex Percentile: Top 45%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.